Weekly Digest – June 2026 Weekly Digest – June 2026 30 May 2026: MediLink Therapeutics announces B7-H3 ADC YL201 met primary endpoint in phase 3 Nasopharyngeal carcinoma study MediLink Therapeutics has announced that its B7-H3-targeted ADC YL201, successfully met the […]
Weekly Digest – May 2026 Weekly Digest – May 2026 18 May 2026: TroFuse-005 trial evaluating Sacituzumab Tirumotecan met primary endpoints of OS and PFS in certain patients with advanced or recurrent Endometrial cancer Merck & Co. announced that the […]
Weekly Digest – May 2026 Weekly Digest – May 2026 19 May 2026: Hengrui announces phase 3 trial of HER3 ADC SHR-A2009 for EGFR-mutant advanced NSCLC met primary endpoint of PFS Jiangsu Hengrui Pharmaceuticals announced that its HER3-directed ADC SHR-A2009 […]
Weekly Digest – May 2026 Weekly Digest – May 2026 21 May 2026: Kelun-Biotech announces phase 3 trial of Sacituzumab Tirumotecan versus Chemotherapy as 1L treatment for advanced TNBC met primary endpoint of PFS Sichuan Kelun-Biotech Biopharmaceutical announced that the […]
Weekly Digest – April 2026 Weekly Digest – April 2026 23 April 2026: Mabwell initiates phase 3 clinical study of its Nectin-4 targeting ADC 9MW2821 for the treatment of TNBC Mabwell announced the initiation of a Phase 3 clinical trial […]
Weekly Digest – March 2026 Weekly Digest – March 2026 20 March 2026: Alphamab Oncology announces the first patient dosed in a Phase 3 clinical study for triple-negative breast cancer of TROP2/HER3 bispecific ADC JSKN016 Alphamab Oncology has reached a […]
Weekly Digest – March 2026 Weekly Digest – March 2026 16 March 2026: CytomX’s Varsetatug Masetecan continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer CytomX Therapeutics has strengthened its position in next-generation […]
Weekly Digest – October 2025 Weekly Digest – October 2025 29 September 2025: Enhertu demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase 3 trial in patients with high-risk early breast cancer […]
Weekly Digest – July 2025 Weekly Digest – July 2025 10 July 2025: PDS Biotech announces colorectal cancer cohort of Phase 2 clinical trial with PDS01 ADC met criteria for expansion to stage 2 following positive stage 1 results PDS […]
Weekly Digest – July 2025 Weekly Digest – July 2025 08 July 2025: Avenzo Therapeutics announces first patient dosed in Phase 1/2 clinical study of AVZO-1418, a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate Avenzo Therapeutics has dosed the first patient […]
